Histidine metabolism drives liver cancer progression via immune microenvironment modulation through metabolic reprogramming
Histidine metabolism drives tumor cell metabolic reprogramming and reshapes the tumor immune microenvironment through intercellular communication, thereby promoting tumor progression. BUD23 shows promise as a biomarker for prognosis and immune response prediction in liver cancer. This study provides new therapeutic targets and theoretical support for liver cancer treatment by targeting histidine metabolism.
Authors
- Haiqing Ma (ORCID: https://orcid.org/0000-0002-5524-6097)
- Fan Xing
- Jiayao Liu
- Peixu Lin
- Jie Wang (ORCID: https://orcid.org/0000-0001-7870-0646)
- Pengcheng Liu (ORCID: https://orcid.org/0000-0002-9530-9267)
- Peipei Zhou (ORCID: https://orcid.org/0000-0001-9033-2559)
- Huanhuan Sun
- Fuxin Huang
Institutions
- Shanxi Medical University (CN)
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
- Shanxi Provincial People’s Hospital (CN)
- Southern Medical University (CN)
- South China University of Technology (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1186/s12967-025-06267-y
- Citations
- 17
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 13.70
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province